Type 1 Diabetes (Juvenile Diabetes) accounted for a 7.3% share of the global clinical trials within the Metabolic Disorders therapy area in 2021, registering a decrease of 0.7% when compared with the last ten-year average of 8.0% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Type 1 Diabetes (Juvenile Diabetes)
Industry sponsored trials held a 47.2% share of all the clinical trials for Type 1 Diabetes (Juvenile Diabetes) indication in 2021, registering an increase of 1.4% when compared with the ten-year average of 45.8%. Non-industry sponsored trials accounted for a 52.8% share in 2021, marking a decrease of 1.4% over the ten-year average of 54.2%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEurope was the top region for industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials, accounting for a 38.9% share in 2021, when compared with the five-year average of 48.6% and ten-year average of 47.5%.
North America was at the second position with a 37.0% share in 2021, over the five-year average of 37.6% and ten-year average of 41.7%, followed by Asia-Pacific with a 37.0% share in 2021, as against five-year and ten-year averages of 30.4% and 28.1% respectively.
Middle East and Africa stood fourth with a 9.3% share in 2021, compared with the five-year average of 6.8% and ten-year average of 8.4%, followed by South and Central America with a 5.6% share in 2021, over five-year and ten-year averages of 4.1% and 4.3% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials, accounting for a 31.5% share in 2021, as against the five-year average of 33.5% and ten-year average of 38.7%.
China held a 16.7% share in 2021, over the five-year average of 8.8% and ten-year average of 5.6%, followed by Canada with a 13.0% share in 2021, compared with the five-year and ten-year averages of 10.1% and 10.7% respectively.
India held a 13.0% share in 2021, as against the five-year average of 8.3% and ten-year average of 6.9%.
The UK held a 9.3% share in 2021, over the five-year and ten-year averages of 7.3% and 8.0% respectively.
Top regions of non-industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials
North America was the top region for non-industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials, accounting for a 37.5% share in 2021 when compared with the five-year average of 38.3% and ten-year average of 35.4%.
Europe was at the second position with a 26.6% share in 2021, over the five-year and ten-year averages of 28.0% and 34.6% respectively, followed by Asia-Pacific with a 25.0% share in 2021, as against the five-year average of 24.2% and ten-year average of 22.1%.
Middle East and Africa stood at the fourth position with a 10.9% share in 2021, compared with the five-year average of 11.4% and ten-year average of 9.5%, followed by South and Central America with a 1.6% share in 2021, over the five-year and ten-year averages of 1.1% and 1.9% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for non-industry sponsored Type 1 Diabetes (Juvenile Diabetes) trials, accounting for a 31.3% share in 2021, as against the five-year average of 28.8% and ten-year average of 27.8%.
China held a 7.8% share in 2021, over the five-year average of 7.0% and ten-year average of 5.5%, followed by Australia with a 6.3% share, compared with the five-year and ten-year averages of 6.0% and 5.2% respectively.
Canada held a 6.3% share in 2021, as against the five-year average of 10.4% and ten-year average of 8.7%.
Iran held a 6.3% share in 2021, over the five-year average of 5.6% and ten-year average of 4.6%.
Phase I trials lead industry sponsored clinical trials for Type 1 Diabetes (Juvenile Diabetes) in 2021
Phase I trials held a 41.7% share of industry sponsored clinical trials for Type 1 Diabetes (Juvenile Diabetes) in 2021, over the five-year average of 41.2% and ten-year average of 42.0%.
Phase II trials held a 38.3% share in 2021, as against the five-year average of 30.1% and ten-year average of 28.4%. Phase IV trials held an 11.7% share in 2021, compared with the five-year and ten-year averages of 9.3% and 9.7% respectively.
Phase III trials held an 8.3% share in 2021, over the five-year average of 19.5% and ten-year average of 19.9%.
Phase II trials lead non-industry sponsored clinical trials for Type 1 Diabetes (Juvenile Diabetes) in 2021
Phase II trials held a 50.7% share of non-industry sponsored clinical trials for Type 1 Diabetes (Juvenile Diabetes) in 2021, over the five-year average of 53.0% and ten-year average of 53.0%.
Phase IV trials held a 25.4% share in 2021, as against the five-year average of 22.1% and ten-year average of 22.5%. Phase I trials held an 11.9% share, compared with the five-year and ten-year averages of 12.8% and 12.5% respectively.
Phase III trials held a 11.9% share in 2021, over the five-year average of 12.1% and ten-year average of 12.0%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
